Projects per year
Personal profile
Research Strategic Pillar
The Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where Megan Berman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Active
-
A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults
Berman, M. (PI)
Merck Sharp and Cohme Corporation ( Award # )
4/1/22 → 3/31/27
Project: Research project
-
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine
Berman, M. (PI)
Merck Sharp and Cohme Corporation ( Award # )
10/29/21 → 10/28/26
Project: Research project
Research output
- 11 Article
-
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial
the DMID 17-0090 Study Group, Feb 15 2024, In: Journal of Infectious Diseases. 229, 2, p. 327-340 14 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Disseminated vaccine-induced varicella infection in a kidney transplant recipient
Berman, M. A. & Rupp, R. E., Nov 2023, In: American Journal of Transplantation. 23, 11, p. 1806-1810 5 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
the DMID 21-0012 Study Group, Dec 2023, In: npj Vaccines. 8, 1, 98.Research output: Contribution to journal › Article › peer-review
Open Access18 Scopus citations -
Risk of COVID-19 after natural infection or vaccination
the NIAID-funded COVID-19 Prevention Network (CoVPN), Oct 2023, In: EBioMedicine. 96, 104799.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
the DMID 21-0012 Study Group, Jul 19 2022, In: Cell Reports Medicine. 3, 7, 100679.Research output: Contribution to journal › Article › peer-review
Open Access126 Scopus citations